Crewe Advisors’s Arbutus Biopharma ABUS Stock Holding History

Crewe Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-56	Closed	-$129	–	586
2023 Q2	$129	Buy	+56	New	+$146	﹤0.01%	813

Other funds holding ABUS

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Crewe Advisors's ABUS Position: Q3 2023 in Review

Crewe Advisors sold out of Arbutus Biopharma (ABUS) in Q3 2023, closing a stake of 56 shares — an estimated $129 sold.

Crewe Advisors first reported a position in ABUS in Q2 2023 and held it in 1 quarter. The position peaked at $129 in Q2 2023. 99 funds tracked by Wall St. Rank hold ABUS as of Q3 2023.

Crewe Advisors reported no remaining Arbutus Biopharma position as of Q3 2023 after selling out during the quarter.
Crewe Advisors sold 56 Arbutus Biopharma shares in Q3 2023, an estimated $129.
Crewe Advisors first reported a position in Arbutus Biopharma in Q2 2023 and held it in 1 quarter.
Crewe Advisors's Arbutus Biopharma position peaked at $129 in Q2 2023.
99 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2023.

Based on Crewe Advisors's 13F filing for Q3 2023, filed 9 Nov 2023.